MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder

MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder

Source: 
Genetic Engineering News
snippet: 

NYC-based clinical-stage biopharmaceutical company Mind Medicine (MindMed) announced that Swiss collaborators at the University Hospital Basel (UHB) and the University Hospital of Psychiatry have released positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of major depressive disorder (MDD).